1. Home
  2. BRLT vs COCP Comparison

BRLT vs COCP Comparison

Compare BRLT & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brilliant Earth Group Inc.

BRLT

Brilliant Earth Group Inc.

HOLD

Current Price

$1.41

Market Cap

18.9M

ML Signal

HOLD

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

N/A

Current Price

$1.22

Market Cap

21.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BRLT
COCP
Founded
2005
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
21.6M
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
BRLT
COCP
Price
$1.41
$1.22
Analyst Decision
Hold
Strong Buy
Analyst Count
4
1
Target Price
$1.70
$6.00
AVG Volume (30 Days)
82.8K
50.3K
Earning Date
05-06-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.65
EPS
N/A
N/A
Revenue
$437,483,000.00
$12,712,091.00
Revenue This Year
$6.72
N/A
Revenue Next Year
$4.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.63
N/A
52 Week Low
$1.00
$0.76
52 Week High
$2.90
$2.03

Technical Indicators

Market Signals
Indicator
BRLT
COCP
Relative Strength Index (RSI) 56.74 56.49
Support Level $1.24 $1.17
Resistance Level $1.64 $1.25
Average True Range (ATR) 0.08 0.07
MACD -0.00 -0.00
Stochastic Oscillator 59.09 47.37

Price Performance

Historical Comparison
BRLT
COCP

About BRLT Brilliant Earth Group Inc.

Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Share on Social Networks: